<DOC>
	<DOCNO>NCT01357902</DOCNO>
	<brief_summary>It open-label , randomise , single dose , two-sequence cross-over study . Twenty-four eligible , healthy , Chinese male subject enrol provide write informed consent . Subjects randomise two treatment group 1 day prior first dose day assign regimen sequence ( AB BA ) balance fashion accordance randomisation schedule . Regimen A five lamotrigine 5 mg chewable/dispersible tablet Regimen B one lamotrigine 25 mg standard/compressed tablet . Subjects receive allocate regimen morning Day 1 undergo study assessment 7 day ( Day 8 ) . Subjects receive alternate randomise treatment washout period 14-21 day Day 1 . Subjects undergo assessment period 7 day attend follow-up visit 8-12 day second treatment . The total observation period study 23~34 day . Subjects arrive research unit even lamotrigine dose occasion remain unit 24-h post-dose evaluation complete ( pre-dose , 0.5 , 1 , 1.5 , 2 , 2.5 , 3 , 4 , 6 , 8 , 12 24 h ) . After , subject return home must return unit assessment make 36 , 48 , 72 , 96 , 120 , 144 168 h dose Study Endpoints/Assessments A total 19 serial blood sample ( 5 mL ) collect measurement plasma lamotrigine concentration study assessment . Safety tolerability assessment ( monitor adverse event serious adverse event , routine laboratory determination , vital sign measurement 12-lead electrocardiogram ) conduct throughout study .</brief_summary>
	<brief_title>Lamotrigine Bioequivalence Study Compare Dispersible Tables With Compressed Tablets China</brief_title>
	<detailed_description />
	<mesh_term>Lamotrigine</mesh_term>
	<mesh_term>Anticonvulsants</mesh_term>
	<criteria>1 . According medical history clinical examination , healthy nonsmoking male subject 2 . Between 18 45 year age , inclusive . 3 . Body weight &gt; =50 kg BMI 1924 kg/m2 , inclusive . 4 . Male subject female partner childbearing potential must agree use one follow contraceptive method first dose study treatment follow visit : Condom plus partner use highly effective contraceptive occlusive cap ( diaphragm cervical/vault cap ) plus spermicidal agent ( foam/gel/film/cream/suppository ) , oral contraceptive , injectable progesterone , implant etonogestrel levonorgestrel , estrogenic vaginal ring , percutaneous contraceptive patch , intrauterine device . OR , Abstinence , define sexual inactivity consistent preferred usual lifestyle subject . Periodic abstinence ( e.g . calendar , ovulation , symptothermal , postovulation method ) withdrawal acceptable method contraception . 5 . Good compliance research policy , procedure restriction . 6 . Can read understand inform consent . Informed consent obtain prior admission study . 7 . No abnormality reveal laboratory test , slight abnormality judge investigator clinical significance . 8 . Aspartate aminotransferase ( AST ) , ALT , alkaline phosphatase bilirubin= &lt; 1.5 x upper limit normal ( ULN ) . 9 . Normal systolic ( 90140 mmHg ) diastolic ( &lt; 90 mmHg ) blood pressure screening , normal pulse ( supine ) . 10 . A normal 12lead ECG prestudy screen . 11 . Single average QT duration correct heart rate Bazett 's formula ( QTcB ) Fridericia 's formula ( QTcF ) &lt; 450 msec ; QTc &lt; 480 msec subject bundle branch block . 12 . Liver serum virological human immunodeficiency virus test negative 1 . Any clinically relevant abnormality identify screen history physical laboratory examination significant cardiovascular , neurological , psychiatric , haematological renal abnormality . 2 . Definite suspect personal history family history adverse reaction hypersensitivity study drug drug similar chemical structure . 3 . Participation clinical trial within 30 day start study . 4 . The subject receive prescribed medication overthecounter ( OTC ) medicine include herbal medicine within 14 day first dose day . The use lubricant spermicide contraceptive barrier device contraceptive permit . 5 . History clinically significant illness within 4 week study . 6 . History clinically significant physical organic abnormality . 7 . Abnormalities 12lead ECG investigator think increase risk participation study . 8 . History liver dysfunction jaundice , hepatitis B surface antigen ( HBsAg ) hepatitis C antibody ( HCAb ) positive regardless ALT level ALT great equal 2times ULN . Subjects Gilbert 's syndrome exclude study . 9 . Positive prestudy screen result hepatitis B antigen , hepatitis C antibodies HIV1 HIV2 antibody . 10 . Subject whose HLAB*1502 positive exclude study . 11 . Abuse alcohol , define average weekly intake great 21 unit average daily intake great three unit . One unit equivalent half pint ( ~ 240 mL ) beer , one ( 25 mL ) measure spirit one glass ( 125 mL ) wine . 12 . Positive prestudy drug/alcohol screen . 13 . History obvious active haematological disorder significant blood loss past 3 month . 14 . Subject donate blood within 56day period donate plasma within 1 week prior study . 15 . Subject mentally legally incapacitate . 16 . Any reason Investigators ' discretion</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>June 2011</verification_date>
</DOC>